Rosacea, Botulinum Toxin
Conditions
Brief summary
the goal of this study is to study the clinical efficacy and safety of botox in the treatment of rosacea.
Detailed description
The main objective is to collect patients and then use different injection volumes of botulinum toxin intradermal injection for the treatment of rosacea erythema telangiectasia, and then to evaluate the clinical efficacy and safety of the treatment.
Interventions
you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Meeting the diagnostic criteria of mild to moderate erythema telangiectasis rosette acne; * more than 18 years old; * to obey the rules of the treatment in the study, and can be followed up for 12 weeks; * informed consent;
Exclusion criteria
* Had received facial cosmetic surgery or botulinum toxin treatment within 6 months before this treatment; * due to systemic diseases such as autoimmune diseases or menopause facial flush; * had allergies botulinum toxin; * pregnant or breastfeeding; * other facial skin or oral disease therapy, including research before 4 weeks rose acne accept other treatment; * With basic neuromuscular diseases (such as myasthenia gravis, amyotrophic lateral sclerosis, etc.); * All landowners 4 weeks before the study whether any oral aminoglycoside drugs, benzodiazepines drugs or muscle relaxants; .Was removed during treatment observation data is not complete, incomplete treatment and patients can't take medication as prescribed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CEA score | 2.4,8,12 weeks | Clinical erythema score (CEA) was divided into no, mild, moderate and severe according to the severity of rosacea, corresponding to 0,1,2,3, respectively |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GAIS score | 2.4,8,12 weeks | he Global Aesthetic Improvement Scale (GAIS) score was assessed by the treating physician on the patient's improvement and was divided into four levels: very improved corresponding, substantial improvement, improvement, no change; Corresponding to the best beauty results, significantly improved but not the best, significantly improved, no change |
Other
| Measure | Time frame | Description |
|---|---|---|
| VISIA red zone score | 2.4,8,12 weeks | VISIA Red zone score The patient's face was photographed by VISIA analyzer and corresponding indicators such as feature index and percentage were recorded |
| Dermatology Quality of Life Score (DLQI) | 2.4,8,12 weeks | The Dermatology Life Quality Score (DLQI) is scored by answering multiple questions in which patients self-rate the impact of their current illness on their lives over a period of one week. The answer is divided into four levels, very serious 3 points, severe 2 points, a little 1 point, no 0 points; |
Countries
China
Contacts
Primary ContactJie Dai
Outcome results
None listed